Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accounts Payables (2016 - 2025)

Ocular Therapeutix has reported Accounts Payables over the past 13 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Accounts Payables at $4.2 million for Q4 2025, down 0.53% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (down 0.53% YoY), and the annual figure for FY2025 was $4.2 million, down 0.53%.
  • Accounts Payables for Q4 2025 was $4.2 million at Ocular Therapeutix, down from $6.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for OCUL hit a ceiling of $6.5 million in Q1 2024 and a floor of $3.4 million in Q1 2022.
  • Median Accounts Payables over the past 5 years was $4.2 million (2021), compared with a mean of $4.6 million.
  • Biggest five-year swings in Accounts Payables: soared 69.51% in 2021 and later decreased 28.31% in 2025.
  • Ocular Therapeutix's Accounts Payables stood at $4.6 million in 2021, then grew by 11.56% to $5.1 million in 2022, then fell by 14.33% to $4.4 million in 2023, then fell by 4.85% to $4.2 million in 2024, then decreased by 0.53% to $4.2 million in 2025.
  • The last three reported values for Accounts Payables were $4.2 million (Q4 2025), $6.3 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.